Dianthus Therapeutics, Inc. (NASDAQ:DNTH) Sees Significant Growth in Short Interest

Dianthus Therapeutics, Inc. (NASDAQ:DNTH - Get Free Report) was the recipient of a large growth in short interest in December. As of December 31st, there was short interest totalling 6,000,000 shares, a growth of 6.0% from the December 15th total of 5,660,000 shares. Based on an average daily volume of 250,800 shares, the short-interest ratio is presently 23.9 days. Approximately 31.2% of the company's shares are short sold.

Hedge Funds Weigh In On Dianthus Therapeutics

Large investors have recently made changes to their positions in the business. Quest Partners LLC raised its stake in Dianthus Therapeutics by 112,400.0% during the 3rd quarter. Quest Partners LLC now owns 1,125 shares of the company's stock valued at $31,000 after purchasing an additional 1,124 shares during the period. SG Americas Securities LLC grew its holdings in Dianthus Therapeutics by 9.2% during the 4th quarter. SG Americas Securities LLC now owns 9,653 shares of the company's stock valued at $210,000 after buying an additional 814 shares in the last quarter. The Manufacturers Life Insurance Company bought a new stake in shares of Dianthus Therapeutics during the second quarter valued at approximately $236,000. Fred Alger Management LLC lifted its holdings in shares of Dianthus Therapeutics by 52.5% in the third quarter. Fred Alger Management LLC now owns 9,633 shares of the company's stock worth $264,000 after buying an additional 3,316 shares in the last quarter. Finally, Point72 DIFC Ltd bought a new position in shares of Dianthus Therapeutics during the second quarter worth $334,000. 47.53% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

DNTH has been the subject of several recent research reports. TD Cowen assumed coverage on shares of Dianthus Therapeutics in a report on Friday, December 20th. They set a "buy" rating for the company. Oppenheimer boosted their target price on Dianthus Therapeutics from $48.00 to $52.00 and gave the stock an "outperform" rating in a report on Monday, November 11th. Raymond James raised Dianthus Therapeutics to a "moderate buy" rating in a research note on Thursday, December 12th. Finally, HC Wainwright reaffirmed a "buy" rating and issued a $40.00 price target on shares of Dianthus Therapeutics in a research report on Monday, November 11th. Eight analysts have rated the stock with a buy rating and two have given a strong buy rating to the company's stock. According to MarketBeat.com, the stock has an average rating of "Buy" and an average price target of $46.43.

Dianthus Therapeutics Trading Up 4.1 %

DNTH stock traded up $0.79 during trading on Friday, reaching $20.00. The stock had a trading volume of 156,254 shares, compared to its average volume of 199,749. The firm has a market cap of $592 million, a PE ratio of -8.00 and a beta of 1.74. The stock's 50 day moving average is $23.62 and its two-hundred day moving average is $26.40. Dianthus Therapeutics has a 52 week low of $10.65 and a 52 week high of $33.77.

Dianthus Therapeutics (NASDAQ:DNTH - Get Free Report) last announced its quarterly earnings data on Thursday, November 7th. The company reported ($0.74) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.59) by ($0.15). Dianthus Therapeutics had a negative net margin of 1,250.32% and a negative return on equity of 21.68%. The company had revenue of $2.17 million for the quarter, compared to the consensus estimate of $1.07 million. On average, research analysts anticipate that Dianthus Therapeutics will post -2.61 EPS for the current year.

Dianthus Therapeutics Company Profile

Dianthus Therapeutics, Inc, a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.